FindTrial
Sign In

Optimal timing for Angiotensin Converting Enzyme (ACE) Inhibitor discontinuation in patients undergoing cardiac surgery on cardiopulmonary bypass.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN09881876
Enrollment
Unknown
Registered
2004-09-30
Start date
2003-06-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery: Cardiovascular Surgery Cardiovascular

Interventions

Patients will be randomised to discontinuing their ACE inhibitor 7 days preoperatively or continuing the medication until the morning of operation. 29/08/2012: Please note that this trial was abandon

Sponsors

Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients undergoing elective first time coronary artery surgery on the ACE inhibitor Ramipril will be eligible for the study.

Exclusion criteria

Exclusion criteria: Exclusion criteria are redo procedures and poor left ventricular function (Ejection Fraction <30%).

Design outcomes

Primary

MeasureTime frame
Primary outcome measures are those relating to the presence and treatment of perioperative and postoperative hypotension. Systemic vascular resistance will be measured via Swan-Ganz catheterisation preoperatively and at fixed intervals in the postoperative period. In addition the requirement of vasoconstrictor agents as well as the duration of their use and the total dose administered will be documented.—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026